Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 8 studies | 21% ± 5% | |
natural killer cell | 7 studies | 19% ± 3% | |
CD16-negative, CD56-bright natural killer cell, human | 7 studies | 20% ± 2% | |
endothelial cell | 7 studies | 20% ± 3% | |
B cell | 6 studies | 18% ± 3% | |
epithelial cell | 5 studies | 25% ± 7% | |
CD8-positive, alpha-beta memory T cell | 5 studies | 18% ± 2% | |
mature NK T cell | 4 studies | 16% ± 2% | |
T cell | 4 studies | 21% ± 9% | |
astrocyte | 4 studies | 19% ± 4% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 2% | |
mucosal invariant T cell | 3 studies | 18% ± 2% | |
GABAergic neuron | 3 studies | 29% ± 5% | |
glutamatergic neuron | 3 studies | 38% ± 8% | |
CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
gamma-delta T cell | 3 studies | 20% ± 4% | |
naive B cell | 3 studies | 16% ± 1% | |
plasmacytoid dendritic cell | 3 studies | 24% ± 7% | |
oligodendrocyte | 3 studies | 16% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3010.99 | 459 / 459 | 100% | 24.41 | 1118 / 1118 |
esophagus | 100% | 2274.07 | 1445 / 1445 | 100% | 21.23 | 183 / 183 |
lung | 100% | 2992.52 | 578 / 578 | 100% | 20.13 | 1155 / 1155 |
prostate | 100% | 2449.65 | 245 / 245 | 100% | 17.83 | 501 / 502 |
ovary | 100% | 3641.56 | 180 / 180 | 100% | 14.19 | 429 / 430 |
uterus | 100% | 2863.08 | 170 / 170 | 100% | 17.48 | 457 / 459 |
intestine | 100% | 2601.26 | 966 / 966 | 99% | 16.99 | 524 / 527 |
bladder | 100% | 2445.48 | 21 / 21 | 99% | 15.77 | 501 / 504 |
thymus | 100% | 2780.25 | 653 / 653 | 99% | 17.37 | 601 / 605 |
adrenal gland | 100% | 2662.40 | 258 / 258 | 99% | 15.60 | 228 / 230 |
stomach | 100% | 2040.08 | 359 / 359 | 99% | 16.28 | 283 / 286 |
pancreas | 100% | 1617.40 | 327 / 328 | 99% | 14.51 | 176 / 178 |
kidney | 100% | 1802.49 | 89 / 89 | 98% | 17.40 | 887 / 901 |
skin | 100% | 3202.14 | 1809 / 1809 | 98% | 20.34 | 462 / 472 |
brain | 98% | 1188.74 | 2583 / 2642 | 100% | 15.49 | 704 / 705 |
liver | 100% | 1424.59 | 226 / 226 | 92% | 7.44 | 373 / 406 |
adipose | 100% | 3071.19 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2390.11 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 16.41 | 29 / 29 |
muscle | 100% | 2053.18 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3069.88 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 19.78 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.53 | 1 / 1 |
heart | 98% | 1359.64 | 847 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 10.45 | 75 / 80 |
peripheral blood | 91% | 2005.76 | 841 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0032786 | Biological process | positive regulation of DNA-templated transcription, elongation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0051301 | Biological process | cell division |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0043923 | Biological process | positive regulation by host of viral transcription |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0008024 | Cellular component | cyclin/CDK positive transcription elongation factor complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0070691 | Cellular component | P-TEFb complex |
GO_0005634 | Cellular component | nucleus |
GO_0070063 | Molecular function | RNA polymerase binding |
GO_0003677 | Molecular function | DNA binding |
GO_0061575 | Molecular function | cyclin-dependent protein serine/threonine kinase activator activity |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0097322 | Molecular function | 7SK snRNA binding |
GO_0140693 | Molecular function | molecular condensate scaffold activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CCNT1 |
Protein name | Cyclin-T1 (CycT1) (Cyclin-T) |
Synonyms | |
Description | FUNCTION: Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II) . Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II . .; FUNCTION: (Microbial infection) In case of HIV or SIV infections, binds to the transactivation domain of the viral nuclear transcriptional activator, Tat, thereby increasing Tat's affinity for the transactivating response RNA element (TAR RNA). Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes. . |
Accessions | O60563 ENST00000618666.4 [O60563-2] ENST00000261900.8 [O60563-1] ENST00000417344.2 [O60563-2] |